APA Citatie

Pacheco, J. M., Gao, D., & Camidge, D. R. (2019). Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain. Ann Transl Med.

Chicago Style citaat

Pacheco, Jose M., Dexiang Gao, en D. Ross Camidge. "Extended Follow-up On KEYNOTE-024 Suggests Significant Survival Benefit for Pembrolizumab in Patients With PD-L1 ≥50%, but Unanswered Questions Remain." Ann Transl Med 2019.

MLA citatie

Pacheco, Jose M., Dexiang Gao, en D. Ross Camidge. "Extended Follow-up On KEYNOTE-024 Suggests Significant Survival Benefit for Pembrolizumab in Patients With PD-L1 ≥50%, but Unanswered Questions Remain." Ann Transl Med 2019.